Matthew J. Plunkett
Director of Finance/CFO presso APOLLOMICS, INC.
Profilo
Matthew J.
Plunkett's current job is as the Chief Financial Officer at Apollomics, Inc. Dr. Plunkett's former jobs include being a Managing Director at Oppenheimer & Co., Inc. from 2000 to 2009, a Managing Director at CIBC World Markets Corp.
in 2008 and 2009, the Chief Business Officer & Executive Vice President at CTI BioPharma Corp.
from 2012 to 2017, a Research Scientist at Sunesis Pharmaceuticals, Inc., a Research Scientist at Axys Advanced Technologies, Inc., the Chief Financial Officer at the California Institute for Regenerative Medicine from 2011 to 2012, the Chief Financial Officer & Vice President at iPierian, Inc. from 2009 to 2011, the Chief Financial Officer at Imago BioSciences, Inc. in 2021, the Chief Financial & Business Officer at Medeor Therapeutics, Inc. from 2017 to 2018, the Chief Financial Officer at Nkarta, Inc. from 2019 to 2020, and the Chief Financial Officer at Aeovian Pharmaceuticals, Inc.Dr. Plunkett's education includes an undergraduate degree from Harvey Mudd College and a doctorate degree from the University of California, Berkeley.
Posizioni attive di Matthew J. Plunkett
| Società | Posizione | Inizio |
|---|---|---|
| APOLLOMICS, INC. | Director of Finance/CFO | 04/03/2024 |
Precedenti posizioni note di Matthew J. Plunkett
| Società | Posizione | Fine |
|---|---|---|
| IMAGO BIOSCIENCES, INC. | Director of Finance/CFO | 28/09/2021 |
| NKARTA, INC. | Director of Finance/CFO | 02/10/2020 |
Medeor Therapeutics, Inc.
 Medeor Therapeutics, Inc. Medical/Nursing ServicesHealth Services Medeor Therapeutics, Inc. engages in medical industry. It provides services which are dedicated to the discovery, development, and commercialization of transformative and personalized cellular therapeutics. The company was founded by Samuel Strober, Edgar Engleman, Robert Lowsky, and Chih Ping in 2012 and is headquartered in South San Francisco, CA. | Director of Finance/CFO | 01/11/2018 |
| CTI BIOPHARMA CORP. | Corporate Officer/Principal | 22/08/2017 |
| California Institute for Regenerative Medicine | Director of Finance/CFO | 01/08/2012 |
Formazione di Matthew J. Plunkett
| Harvey Mudd College | Undergraduate Degree |
| University of California, Berkeley | Doctorate Degree |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
| Società quotate in Borsa | 2 |
|---|---|
| NKARTA, INC. | Health Technology |
| APOLLOMICS, INC. | Health Technology |
| Aziende private | 10 |
|---|---|
CTI BioPharma Corp.
 CTI BioPharma Corp. Pharmaceuticals: MajorHealth Technology CTI BioPharma Corp. is a biopharmaceutical company, which engages in the development, acquisition, and commercialization of novel targeted therapies for blood-related cancers. It focuses on evaluating pacritinib, its sole product candidate currently in active development, for the treatment of adult patients with myelofibrosis. The company was founded by James A. Bianco, Jack W. Singer, and Louis A. Bianco in September 1991 and is headquartered in Seattle, WA. | Health Technology |
Oppenheimer & Co., Inc.
 Oppenheimer & Co., Inc. Investment ManagersFinance Oppenheimer & Co., Inc. provides security brokerage services. It also offers investment banking and advice to high net worth investors, individuals, businesses and institutions. The company is headquartered in New York, NY. | Finance |
Sunesis Pharmaceuticals, Inc.
 Sunesis Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sunesis Pharmaceuticals, Inc. engages in the development and commercialization of new oncology therapeutics for the treatment of solid and hematologic cancers. The firm's activities include conducting research and development internally and through corporate collaborators, in-licensing and out-licensing pharmaceutical compounds and technology, conducting clinical trials and raising capital. The company was founded on February 10, 1998 and is headquartered in South San Francisco, CA. | Health Technology |
Axys Advanced Technologies, Inc.
 Axys Advanced Technologies, Inc. Medical SpecialtiesHealth Technology Part of Infinity Pharmaceuticals, Inc., Axys Advanced Technologies, Inc. produces and markets novel compound diversity libraries for drug screening. Axys Advanced Technologies was acquired by Discovery Partners International, Inc. from Axys Pharmaceuticals, Inc. on April 28, 2000 for $60 million. | Health Technology |
| California Institute for Regenerative Medicine | Government |
iPierian, Inc.
 iPierian, Inc. Pharmaceuticals: MajorHealth Technology ierian, Inc. developed and manufactured biopharmaceutical products. The firm's lead antibody, IPN007, represents a new approach to treating neurodegenerative disease by targeting a novel form of secreted Tau protein. The company was founded in 2007 and is headquartered in South San Francisco, CA. | Health Technology |
CIBC World Markets Corp.
 CIBC World Markets Corp. Investment Banks/BrokersFinance Founded in 1969, CIBC World Markets Corp. is a broker/dealer located in New York City. The firm is a subsidiary of the Canadian Imperial Bank of Commerce. The firm provides a range of credit and capital market products, investment banking and merchant banking services in North America and worldwide. They offer a range of advisory services, as well as underwrite debt, credit and equity products for corporate, government and institutional clients. CIBC world Markets Corp. also provides equity products and services, fixed-income services, foreign exchange products and solutions, securitization and credit structuring services, as well as trades and distributes short-term debt instruments. In addition, the firm originates financial solutions including credit products for medium-sized businesses in Canada. They also provide private equity, mezzanine and bridge financing to companies in North America, Europe and Australia. The company is based in New York City | Finance |
Imago BioSciences, Inc.
 Imago BioSciences, Inc. BiotechnologyHealth Technology Imago BioSciences, Inc. operates as a clinical-stage biopharmaceutical company that develops novel anti-cancer therapeutics. It translates science of genetics and epigenetics enzymes into novel medicines for treating myeloid diseases that pose challenges to patients, families, and physicians. The company also translates insights into transformative therapies that alter the history of disease allowing patients to live longer and disease-free lives. Imago BioSciences was founded by Hugh Young Rienhoff, Jr., Laura G. Eichorn and Jennifer Peppe on March 29, 2012 and is headquartered in Redwood City, CA. | Health Technology |
Medeor Therapeutics, Inc.
Medeor Therapeutics, Inc. Medical/Nursing ServicesHealth Services Medeor Therapeutics, Inc. engages in medical industry. It provides services which are dedicated to the discovery, development, and commercialization of transformative and personalized cellular therapeutics. The company was founded by Samuel Strober, Edgar Engleman, Robert Lowsky, and Chih Ping in 2012 and is headquartered in South San Francisco, CA. | Health Services |
Aeovian Pharmaceuticals, Inc.
 Aeovian Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aeovian Pharmaceuticals, Inc. engages in the development of pharmaceuticals. It offers inhibitors for the treatment of rare and age-related diseases. The company was founded by Stelios T. Tzannis in 2012 and is headquartered in Novato, CA. | Health Technology |
- Borsa valori
- Insiders
- Matthew J. Plunkett
